24/7 Market News Snapshot 27 February, 2025 – MAIA Biotechnology, Inc. (NYSE:MAIA)

February 27, 2025

DENVER, Colo., 27 February, 2025 (247marketnews.com) – (NYSE:MAIA) are discussed in this article.
MAIA Biotechnology, Inc. has entered the trading sphere with notable momentum, starting at $1.88 and seeing a rise to $2.005, which marks an increase of approximately 8.97% from the previous day’s close of $1.84. The trading volume, currently at 531.25K, indicates heightened investor interest, likely propelled by favorable news regarding the company’s innovative biopharmaceutical initiatives. Market analysts suggest that maintaining support above the $2.00 threshold could signal further gains, inviting traders to closely observe resistance levels and volume trends to gauge sustained momentum.

Complementing this surge in activity is the company’s announcement of a pivotal Phase 3 clinical trial set to commence in 2025, designated THIO-104. This trial aims to evaluate the efficacy of THIO, a groundbreaking immunotherapy, in tandem with a checkpoint inhibitor for patients suffering from third-line non-small cell lung cancer (NSCLC) who are resistant to existing treatments. The multicenter, open-label trial will enroll up to 300 patients, employing a 1:1 randomization methodology to yield pivotal comparative data against standard chemotherapy.

Previously, the Phase 2 THIO-101 trial demonstrated significant improvements over existing treatment methodologies, further bolstering the company’s position in the oncology landscape. Dr. Vlad Vitoc, CEO of MAIA, expressed enthusiasm regarding the clinical trial, emphasizing expectations for THIO to showcase unmatched benefits for advanced-stage NSCLC patients.

The primary goal of the THIO-104 trial is to ascertain overall survival rates in patients treated with THIO and a checkpoint inhibitor, compared to those receiving traditional chemotherapy. Secondary outcomes will encompass measures of disease control, response rates, and safety profiles. Anticipating patient enrollment in the latter half of 2025, MAIA remains resolute in its pursuit of FDA approval for THIO, underlining its determination to enhance treatment outcomes for patients facing limited therapeutic options in the fight against cancer.

Related news for (MAIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.